Trial halted before start for rectal cancer recurrence
NCT ID NCT07223567
Summary
This study aimed to test if a combination of two drugs, regorafenib and lorigerlimab, could shrink rectal cancer tumors that had started to grow back or returned locally after a patient's first round of treatment. The goal was to see if this drug combo could reduce the cancer enough to allow for successful surgical removal. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.